Cancer

Cancer begins in your cells, which are the building blocks of your body. Normally, your body forms new cells as you need them, replacing old cells that die. Sometimes this process goes wrong. New cells grow even when you don't need them, and old cells don't die when they should. These extra cells can form a mass called a tumor. Tumors can be benign or malignant. Benign tumors aren't cancer while malignant ones are. Cells from malignant tumors can invade nearby tissues. They can also break away and spread to other parts of the body.

Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for where they start. For example, lung cancer starts in the lung, and breast cancer starts in the breast. The spread of cancer from one part of the body to another is called metastasis. Symptoms and treatment depend on the cancer type and how advanced it is. Most treatment plans may include surgery, radiation and/or chemotherapy. Some may involve hormone therapy, immunotherapy or other types of biologic therapy, or stem cell transplantation.

NIH: National Cancer Institute

Cancer FDA Approved Drugs

ABRAXANE [Paclitaxel^{C₄₇H₅₁NO₁₄}]

100mg/vial (iv (infusion) for suspension)

Abraxis Bioscience^{Jan 7, 2005}

Treatment of breast cancer.
Treatment of lung cancer.
Treatment of pancreatic cancer.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

ABSTRAL [Fentanyl Citrate^{C₂₂H₂₈N₂OC₆H₈O₇}]

eq 0.1mg base (sublingual tablet)

eq 0.2mg base (sublingual tablet)

eq 0.3mg base (sublingual tablet)

eq 0.4mg base (sublingual tablet)

eq 0.6mg base (sublingual tablet)

eq 0.8mg base (sublingual tablet)

Sentynl Theraps Inc^{Jan 7, 2011}

Management of breakthrough pain in patients with cancer.

efficacy
3.0 (1)

side effects
0.0 (0)

danger
0.0 (0)

AFINITOR [Everolimus^{C₅₃H₈₃NO₁₄}]

10mg (oral tablet)

2.5mg (oral tablet)

7.5mg (oral tablet)

Novartis^{Mar 30, 2009}

Treatment of advanced hormone receptor positive, her2-negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole.
Treatment of patients with progessive neuroendocrine tumors of pancreatic origin (pnet) that are unresectable, locally advanced or metastatic.
Treatment of patients with tuberous sclerosis complex (tsc) who have subependymal giant cell astrocytoma (sega) that requires therapeutic intervention but cannot be curatively resected..
Treatment of solid excretory system tumors; advanced renal cell carcinoma (rcc), after failure of treatment with sunitinib or sorafenib.

efficacy
2.0 (2)

side effects
0.0 (0)

danger
0.0 (0)

ALUNBRIG [Brigatinib^{C₂₉H₃₉ClN₇O₂P}]

30mg (oral tablet)

90mg (oral tablet)

Ariad^{Apr 28, 2017}

Treatment of patients with anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer (nsclc) who have progressed on or are intolerant to crizotinib.

efficacy
3.0 (1)

side effects
0.0 (0)

danger
0.0 (0)

CAMPTOSAR [Irinotecan Hydrochloride^{C₃₃H₃₈N₄O₆ClH3H₂O}]

100mg/5ml (20mg/ml) (injection injectable)

300mg/15ml (20mg/ml) (injection injectable)

40mg/2ml (20mg/ml) (injection injectable)

Pfizer Inc^{Jun 14, 1996}

Use in combination with 5-fluorouracil and leucovorin for the treatment of metastatic colorectal cancer where the dose of leucovorin is at least 200mg per square meter.
Use of irinotecan in combination with 5-fluorouracil and leucovorin for the treatment of metastatic colorectal cancer.

efficacy
5.0 (1)

side effects
0.0 (0)

danger
0.0 (0)

COMETRIQ [Cabozantinib S-malate^{C₂₈H₂₄FN₃O₅C₄H₆O₅}]

eq 20mg base (oral capsule)

eq 80mg base (oral capsule)

Exelixis^{Nov 29, 2012}

Method of treating medullary thyroid cancer.

efficacy
5.0 (1)

side effects
0.0 (0)

danger
0.0 (0)

CYSVIEW KIT [Hexaminolevulinate Hydrochloride^{C₁₁H₂₁NO₃ClH}]

100mg/vial (intravesical for solution)

Photocure Asa^{May 28, 2010}

Detection of non-muscle invasive papillary cancer of the bladder by photodynamic cystoscopy.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

ELIGARD [Leuprolide Acetate^{C₅₉H₈₄N₁₆O₁₂C₂H₄O₂}]

22.5mg/vial (subcutaneous injectable)

30mg/vial (subcutaneous injectable)

45mg/vial (subcutaneous injectable)

7.5mg/vial (subcutaneous injectable)

Tolmar Therap^{Jul 24, 2002}

Method of treating cancer.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

ERIVEDGE [Vismodegib^{C₁₉H₁₄Cl₂N₂O₃S}]

150mg (oral capsule)

Genentech^{Jan 30, 2012}

Method of using vismodegib to treat cancer in a mammal.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

EVISTA [Raloxifene Hydrochloride^{C₂₈H₂₇NO₄SClH}]

60mg (oral tablet)

Lilly^{Dec 9, 1997}

Prevention of osteoporosis in postmenopausal women.
Use for prevention of breast cancer.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

FASLODEX [Fulvestrant^{C₃₂H₄₇F₅O₃S}]

50mg/ml (intramuscular injectable)

Astrazeneca^{Apr 25, 2002}

Treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
Treatment of hr-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with palbococlib in women with disease progression after endocrine therapy.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

FENTORA [Fentanyl Citrate^{C₂₂H₂₈N₂OC₆H₈O₇}]

eq 0.1mg base (buccal, sublingual tablet)

eq 0.2mg base (buccal, sublingual tablet)

eq 0.4mg base (buccal, sublingual tablet)

eq 0.6mg base (buccal, sublingual tablet)

eq 0.8mg base (buccal, sublingual tablet)

Cephalon^{Sep 25, 2006}

Management of breakthrough pain in patients with cancer by buccal or sublingual administration of fentanyl.
Management of breakthrough pain in patients with cancer.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

FIRMAGON [Degarelix Acetate^{C₈₂H₁₀₃ClN₁₈O₁₆C₂H₄O₂H₂O}]

eq 120mg base/vial (subcutaneous powder)

eq 80mg base/vial (subcutaneous powder)

Ferring^{Dec 24, 2008}

Gnrh antagonist indicated for treatment of patients with advanced prostate cancer.
Method of treating prostate cancer.
Treatment of advanced prostate cancer with a reduced likelihood of causing a gonadotrophin releasing hormone agonist side-effect.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

GILOTRIF [Afatinib Dimaleate^{C₂₄H₂₅ClFN₅O₃2C₄H₄O₄}]

eq 20mg base (oral tablet)

eq 30mg base (oral tablet)

eq 40mg base (oral tablet)

Boehringer Ingelheim^{Jul 12, 2013}

Treatment of cancer.
Treatment of patients with advanced (metastatic) non-small cell lung cancer whose disease progressed during or after platinum-based chemotherapy.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

HALAVEN [Eribulin Mesylate^{C₄₀H₅₉NO₁₁CH₄O₃S}]

1mg/2ml (0.5mg/ml) (intravenous solution)

Eisai Inc^{Nov 15, 2010}

Treatment of patients with metastatic breast cancer.
Treatment of patients with unresectable or metastatic liposarcoma.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

IBRANCE [Palbociclib^{C₂₄H₂₉N₇O₂}]

100mg (oral capsule)

125mg (oral capsule)

75mg (oral capsule)

Pfizer Inc^{Feb 3, 2015}

Treating hr-pos., her2-neg. advanced or metastatic breast cancer with palbociclib in combo with an aromatase inhibitor as initial endocrine based therapy in postmenopausal women or fulvestrant in women with disease progression after endocrine therapy.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

IRESSA [Gefitinib^{C₂₂H₂₄ClFN₄O₃}]

250mg (oral tablet)

Astrazeneca Pharms^{Jul 13, 2015}

First-line treatment of patients with metastatic non-small cell lung cancer (nsclc) whose tumors have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations.

efficacy
0.0 (0)

side effects
0.0 (0)

IXEMPRA KIT [Ixabepilone^{C₂₇H₄₂N₂O₅S}]

15mg/vial (iv (infusion) injectable)

45mg/vial (iv (infusion) injectable)

R-pharm Us Llc^{Oct 16, 2007}

A method of treating cancer in a patient comprising administering ixabepilone or pharmaceutical compositions comprising ixabepilone.
Method of treating breast cancer by administering ixabepilone; a method of treating a cancer responsible to microtubule stabilization by administering ixabepilone.
Method of treating cancer in a patient comprising intravenously administering to the patient ixabepilone diluted in a parenteral diluent.
Method of treating cancer, iv admin, lyophylized ixabepilone diluted, every week or 3 weeks; lyophilized ixabepilone with solvent(dehydrated ethanol) diluted to concentration of 0.1mg/ml to 0.9mg/ml.
Method of treating patient comprising mixing first and second vials of product comprising lyophilized ixabepilone to provide an epothilone analog solution, diluting solution with a suitable diluent to prepare intravenous formulation for pt.
Use of ixabepilone in combination with capecitabine in treatment of metastasis breast cancer.

JEVTANA KIT [Cabazitaxel^{C₄₅H₅₇NO₁₄}]

60mg/1.5ml (40mg/ml) (iv (infusion) solution)

Sanofi Aventis Us^{Jun 17, 2010}

Treatment in combination with a corticoid such as prednisone of prostate cancer previously treated iwth docetaxel.

KISQALI [Ribociclib Succinate^{C₂₃H₃₀N₈OC₄H₆O₄}]

eq 200mg base (oral tablet)

Novartis Pharms Corp^{Mar 13, 2017}

In combination with an aromatase inhibitor as initial endocrine-based therapy for treatment of postmenopausal women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her-2)-negative advanced or metastatic breast cancer.

KISQALI FEMARA CO-PACK (COPACKAGED) [Letrozole^{C₁₇H₁₁N₅} : Ribociclib Succinate^{C₂₃H₃₀N₈OC₄H₆O₄}]

2.5mg,n/a : n/a,eq 200mg base (oral tablet, tablet)

Novartis Pharms Corp^{May 4, 2017}

In combination with an aromatase inhibitor as initial endocrine-based therapy for treatment of postmenopausal women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her-2)-negative advanced or metastatic breast cancer.

LAZANDA [Fentanyl Citrate^{C₂₂H₂₈N₂OC₆H₈O₇}]

eq 0.1mg base (nasal spray, metered)

eq 0.3mg base (nasal spray, metered)

eq 0.4mg base (nasal spray, metered)

Depomed Inc^{Jun 30, 2011}

Management of breakthrough pain in cancer patients 18 years of age and older who are receiving and tolerant to opioid therapy for their underlying persistent cancer pain.
Management of breakthrough pain in patients with cancer.

LENVIMA [Lenvatinib Mesylate^{C₂₁H₁₉ClN₄O₄CH₄O₃S}]

eq 10mg base (oral capsule)

eq 4mg base (oral capsule)

Eisai Inc^{Feb 13, 2015}

Method for treating thyroid carcinoma including differentiated thyroid cancer.

LONSURF [Tipiracil Hydrochloride^{C₉H₁₁ClN₄O₂ClH} : Trifluridine^{C₁₀H₁₁F₃N₂O₅}]

eq 6.14mg base : 15mg (oral tablet)

eq 8.19mg base : 20mg (oral tablet)

Taiho Oncology^{Sep 22, 2015}

Treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-vegf biological therapy, and if ras wild-type, an anti-egfr therapy.

LUPRON DEPOT [Leuprolide Acetate^{C₅₉H₈₄N₁₆O₁₂C₂H₄O₂}]

11.25mg/vial (injection injectable)

22.5mg/vial (injection injectable)

3.75mg (injection injectable)

30mg/vial (injection injectable)

45mg/vial (injection injectable)

7.5mg/vial (injection injectable)

Abbvie Endocrine Inc^{Mar 7, 1997}

LYNPARZA [Olaparib^{C₂₄H₂₃FN₄O₃}]

50mg (oral capsule)

Astrazeneca Pharms^{Dec 19, 2014}

Treatment of brca mutated ovarian cancer using parp inhibitor.

NINLARO [Ixazomib Citrate^{C₂₀H₂₃BCl₂N₂O₉}]

eq 2.3mg base (oral capsule)

eq 3mg base (oral capsule)

eq 4mg base (oral capsule)

Millennium Pharms^{Nov 20, 2015}

Method for treating cancer, including multiple myeloma.
Method for treating multiple myeloma with one or more other therapeutic agents.
Method for treating multiple myeloma.

ONIVYDE [Irinotecan Hydrochloride^{C₃₃H₃₈N₄O₆ClH3H₂O}]

eq 43mg base/10ml (eq 4.3mg base/ml) (iv (infusion) injectable, liposomal)

Ipsen Inc^{Oct 22, 2015}

Treatment of exocrine pancreatic cancer that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin.
Treatment of metastatic adenocarcinoma of the pancreas that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin, in a patient homozygous for the ugt1a1*28 allele.
Treatment of metastatic adenocarcinoma of the pancreas that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin.
Treatment of pancreatic cancer that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin.
Treatment of pancreatic cancer.

RUBRACA [Rucaparib Camsylate^{C₁₉H₁₈FN₃OC₁₀H₁₆O₄S}]

eq 200mg base (oral tablet)

eq 250mg base (oral tablet)

eq 300mg base (oral tablet)

Clovis Oncology Inc^{Dec 19, 2016}

A method for treating ovarian cancer by administering rucaparib, wherein the cancer is associated with a deleterious brca mutation.

SPRYCEL [Dasatinib^{C₂₂H₂₆ClN₇O₂SH₂O}]

100mg (oral tablet)

140mg (oral tablet)

20mg (oral tablet)

50mg (oral tablet)

70mg (oral tablet)

80mg (oral tablet)

Bristol Myers Squibb^{May 30, 2008}

A method for the treatment of a protein tyrosine kinase-associated disorder.
A method for the treatment of cancer.
A method for treatment of a cancer, wherein the cancer is chronic myelogenous leukemia.

TAGRISSO [Osimertinib Mesylate^{C₂₈H₃₃N₇O₂CH₄O₃S}]

eq 40mg base (oral tablet)

eq 80mg base (oral tablet)

Astrazeneca Pharms^{Nov 13, 2015}

Treatment of patients with metastatic epidermal growth factore receptor (egfr) t790m mutation-positive non-small cell lung cancer (nsclc), who have progressed on or after egfr tki therapy.

TARCEVA [Erlotinib Hydrochloride^{C₂₂H₂₃N₃O₄ClH}]

eq 100mg base (oral tablet)

eq 150mg base (oral tablet)

eq 25mg base (oral tablet)

Osi Pharms^{Nov 18, 2004}

First-line treatment of locally advanced unresectable or metastatic pancreatic cancer, in combination with gemcitabine.
First-line treatment of metastatic non smal-cell lung cancer (nsclc) with egfr exon 19 deletions or exon 21 (l858r) substitution mutations as detected by an fda-approved test.
Maintenance treatment in patients with locally advanced or metastatic nsclc who have not progressed on 1st-line treatment wth platinum-based chemotherapy.
Maintenance treatment of patients with locally advanced or metastatic nsclc whose disease has not progressed after four cycles platinum-based chemotherapy.
Treatment of locally advanced or metastatic non small-cell lung cancer (nsclc) after failure of at least one prior chemotherapy regimen.

TYKERB [Lapatinib Ditosylate^{C₂₉H₂₆ClFN₄O₄S2C₇H₈O₃SH₂O}]

eq 250mg base (oral tablet)

Novartis Pharms Corp^{Mar 13, 2007}

Treatment of patients with advanced or metastatic breast cancer whose tumors overexpress her2 and who have received prior therapy including anthracycline, a taxane and trastuzumab.
Treatment of patients with breast cancer whose tumors overexpress the her2 receptor.

VARUBI [Rolapitant Hydrochloride^{C₂₅H₂₆F₆N₂O₂ClHH₂O}]

eq 90mg base (oral tablet)

Tesaro Inc^{Sep 1, 2015}

Prevention of delayed nausea and vomiting associated with emetogenic cancer chemotherapy.

XALKORI [Crizotinib^{C₂₁H₂₂Cl₂FN₅O}]

200mg (oral capsule)

250mg (oral capsule)

Pf Prism Cv^{Aug 26, 2011}

Treatment of a cancer mediated by an anaplastic lymphoma kinase (alk).

XTANDI [Enzalutamide^{C₂₁H₁₆F₄N₄O₂S}]

40mg (oral capsule)

Astellas^{Aug 31, 2012}

The treatment of patients with metastatic castration-resistant prostate cancer (crpc)..
The treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel.

ZYKADIA [Ceritinib^{C₂₈H₃₆ClN₅O₃S}]

150mg (oral capsule)

Novartis Pharms Corp^{Apr 29, 2014}

Treatment of a cancer mediated by an anaplastic lymphoma kinase (alk).

ZYTIGA [Abiraterone Acetate^{C₂₆H₃₃NO₂}]

250mg (oral tablet)

500mg (oral tablet)

Janssen Biotech^{Apr 28, 2011}

Use in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer who had received prior docetaxel chemotherapy.
Use in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel.
Use in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer.

WARNING: Consult a licensed physician in the appropriate field for medical treatment and drug prescription. Do not self medicate.

WARNING: All medicines, drugs, plants, chemicals or medicial precedures below are for historical reference only. Many of these treatments are now known to be harmful and possibly fatal. Do not consume any plant, chemical, drug or otherwise without first consulting a licensed physician that practices medine in the appropriate field.

Felter's Materia Medica on Cancer

CONDURANGO
The bark of Gonolobus Cundurango, Triana (Marsdenia Condurango, Reichenbach) (Nat. Ord. Asclepiadaceae). South America, especially Ecuador. Common... / ...Therapy.A drug of considerable power, introduced into medicine in 1871 as a cure for syphilis and cancer of the stomach, in both of which it has but an unsustained reputation. It is thought, however... / ...powerfully upon the nervous system, inducing in animals, impaired appetite, vomiting, ptyalism, muscular weakness, convulsions, and paralysis.¹

CONIUM
.... Therapy.External. Locally applied extract of conium, or the powdered drug, relieves the pain of cancerous growths and ulcers. Locke advised, Rx. English Extract of Conium, 2 drachms; Petrolatum, 6......east; therefore it is safe to assume that such nodules as are influenced by conium are probably not cancerous, but more than likely of a strumous character. At any rate we are not justified in delayin...¹

ECHINACEA
The dried root of Brauneria angustifolia, Linné (Echinacea angustifolia [DeCandolle], Heller). (Nat. Ord. Compositae.) In rich prairie soils of... / ...ulcerations, fetid discharges from the ears, and in gangrene. While not wholly masking the odor of cancer and gangrene it reduces it greatly, much to the comfort of the sick and the attendants. Echin... / ...cent solution to full strength echinacea or echafolta may be freely used, syringing the channels with it. This gives great relief from pain ¹

EUCALYPTUS^EUAN12
The leaves of Eucalyptus Globulus, Labillardiere. Collected from the older parts of the tree. (Nat. Ord. Myrtaceae.) A native tree of Australia;... / ...ic diseases of the bronchopulmonic tract, with fetor, relaxation and abundant secretions. Used upon cancerous surfaces they mask the fetid odor and give some relief from pain. The following is an idea... / ...Used according to indications as given above, eucalyptus is a very satisfactory and pleasant medicine. It is best given in syrup or glycerin.¹

FICUS
The fleshy receptacle of Ficus Carica, Linné bearing fruit on its inner surface. (Nat. Ord. Moraceae.) Persia and Asia Minor; cultivated in all... / .... The great surgeon, Billroth, employed a poultice of dried figs and milk to overcome the stench of cancerous and fetid ulcers. Internal. Nutritive, demulcent, and aperient. Figs are frequently resort... / ...dates, raisins, prunes, and senna leaves. This is wrapped in tinfoil, and sliced off and eaten according to the requirements of the individual.¹

TRIFOLIUM
The blossoms of Trifolium Pratense, Linné (Nat. Ord. Leguminosae). Cultivated everywhere. Common Name: Red Clover. Principal Constituents.Resins and... / ...gnant neoplasms. Though by no means curative in carcinoma, patients who have been operated upon for cancer are slower in redeveloping the growths when given tincture of trifolium daily.¹

Physician's Materia Medica on Cancer

ARBOR VITAE
The leafy twigs of THUJA OCCIDENTALIs, Lin. Antiperiodic, iebrifuge, emmenagogue, alterative, anthelmintlo, anti-scorbutic. Used locally as an antiseptic and stimulant wash for cancerous ul cerations; internally in malarial fevers, chronic bronchitis, scurvy and rheumatism.²

CANCER-ROOT^CONOP
The root of LEPTAMNIUM VIRGINIANUM, (L.) Raf. an efficient astringent.²

CONIUM (Poison Hemlock)
The immature fruit, also the leaves (unoflicial), oi CONIUM MACULATUM, Lin. Sedative, discutient, antispasmodic, anaphro disiac. Prescribed in cutaneous diseases, cancer and scrofulous indurations for its resolvent action, and in tetanus, chorea and acute mania as an antispasmodic and sedative.²

References

1) Felter, Harvey Wickes, 1922, The Eclectic Materia Medica, Pharmacology and Therapeutics, Cincinnati, Ohio.
2) Nelson, Baker & Co., 1904, Physician's Handy Book of Materia Medica and Therapeustics, Detroit, Michigan.

Ledgend of Medicine

MODERN MEDICINES

HOME REMEDIES

RANDOM DRUGS

RANDOM AILMENTS

Cancer

Cancer FDA Approved Drugs

Felter's Materia Medica on Cancer

Physician's Materia Medica on Cancer

References